

OKLAHOMA HEART INSTITUTE TO BECOME FOURTH U.S. SITE FOR VISABL-AFL

3 February 2026 – Melbourne, Australia **(2 February 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that Oklahoma Heart Institute **(OHI)** has contracted with Imricor to join Imricor's VISABL-AFL clinical trial, supporting the U.S. FDA approval process for Imricor's ablation products. OHI is now the fourth U.S. site to join the trial.

Oklahoma Heart Institute joins the University of Virginia (UVA) Health, Virginia Commonwealth University (VCU) Health and Johns Hopkins University (JHU) as U.S. sites participating in the VISABL-AFL trial.

Oklahoma Heart Institute is a specialty hospital with established cardiology-owned cardiac MRI (CMR) facilities. Cardiology ownership of MRI infrastructure can materially reduce capital and organisational barriers to adoption and accelerate the implementation of interventional cardiac MRI (iCMR) procedures. Imricor has identified multiple U.S. hospitals with existing cardiology owned MRI infrastructure, which management believes represents a favourable pathway to faster market adoption and lower hospital capital expenditure.

The addition of OHI as a fourth U.S. enrolling site is expected to accelerate patient recruitment for VISABL-AFL, supporting a more efficient FDA approval process. Increased U.S. enrolment capacity also allows European trial sites to complete participation sooner and return to revenue generating clinical activity.

Procedures at OHI are expected to commence in March.

The Principal Investigator for VISABL-AFL at Oklahoma Heart Institute is Dr. Edward T. Martin, the Director of Cardiovascular Magnetic Resonance Imaging at OHI, and a rare Master of the Society for Cardiovascular Magnetic Resonance (MSCMR).

Dr. Martin commented: “I have been involved with the imaging aspect of cardiac MRI for the last 30 years, and I have seen and participated in many exciting technological advances over that time. I am extremely excited to see the advancements in hardware, software and catheter development that allow expansion of cardiac MRI into interventional electrophysiology and am eager to get started with the project. I think cardiac MRI has the potential to aid in ablation success.”

Imricor's Chair and CEO, Steve Wedan, added: “Oklahoma Heart Institute represents a highly sophisticated cardiology-led model of care, with the clinical vision and infrastructure already in place to support advanced MRI-guided procedures. The fact that cardiology owns and operates their MRI system creates a streamlined environment for innovation, reducing organisational complexity while enabling physicians to focus on delivering the best possible outcomes for patients.

“Dr. Martin is a worldwide cardiovascular MR leader, and we are delighted to welcome him and his team at the Oklahoma Heart Institute to VISABL-AFL. We look forward to working closely with them as we advance the trial efficiently and continue building momentum toward FDA approval.”

VISABL-AFL Clinical Trial Sites



PROF. JUERG SCHWITTER

MD, Director Cardiac MR Centre, University Hospital Lausanne (CHUV)



"Many years ago in San Francisco, we did pioneering work on coronary artery disease detection by MRI. Now ischemia diagnostics by MRI is in all international guidelines. Similarly, pacemakers and defibrillators were not compatible with MRI 10 years ago. We started a collaboration with industry, and now all leading device manufactures offer a full spectrum of devices, all MRI compatible, reaching market shares up to 100%. **I believe strongly, that this evolution will also happen to the iCMR field, as it allows for high precision interventions**, where we expect higher success rate, lower relapse rate and less complications compared to conventional techniques, and all these advantages go without radiation exposure and potentially shorter interventions times."



DR. AV KOLANDAIVELU

Johns Hopkins University



"MRI is the gold standard for imaging arrhythmia causing heart characteristics, like fibrosis, and for visualizing the effects of ablation. We are enthusiastic to be a part of the FDA approval study for the Imricor ablation system."



DR. KENNETH BILCHICK

University of Virginia Health



"Interventional CMR, particularly for electrophysiology applications, promises to advance our therapeutic strategies for patients with atrial and ventricular arrhythmias by facilitating visualization of the catheters used for ablation simultaneously with real-time CMR imaging."



DR. AJAY PILLAI

Virginia Commonwealth University Health



"Imricor's Northstar mapping system and Vision-MR mapping and ablation catheters **represent a paradigm shift in cardiac ablation**. The potential to visualize arrhythmogenic substrate and, crucially, the effects of ablation is extraordinarily impactful and meaningful for patient outcomes."



DR. MARCO GÖTTE

Amsterdam University Medical Center



"With MRI-guided treatment of heart conditions, we are working towards fewer procedures per patient, hospital admissions, and less medication. Perhaps MRI-guided treatment of heart disease **will become the norm** and replace X-ray-driven treatments."



DR. LAURENT FIORINA

Cardiovascular Institute of South Paris



"Performing procedures with Imricor's NorthStar 3D Mapping System **is a game changer for this field**, and it will have a transformative impact. I look forward to the continued partnership with Imricor."



DR. EDWARD MARTIN

Oklahoma Heart Institute



"I have been involved with the imaging aspect of cardiac MRI for the last 30 years, and I have seen and participated in many exciting technological advances over that time. I am extremely excited to see the advancements... that allow expansion of cardiac MRI into interventional electrophysiology."

**ENDS**

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

For personal use only



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.